2026 Q2 -tulosraportti
25 päivää sitten
‧30 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | NON | NON | ||
| 9 090 | SHB | AVA | ||
| 7 000 | SHB | AVA | ||
| 23 910 | SHB | NON | ||
| 1 000 | AVA | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 19.8. | ||
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 19.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8.9. · Muokattuhttps://analystgroup.se/bolag/acucort/kommentar-pa-acucorts-beviljade-varumarkesskydd-av-zeqmelit-i-ukraina Our view on AcuCort as an investment AcuCort is a pharmaceutical company that has developed the innovative oral film Zeqmelit®, based on the corticosteroid substance dexamethasone for rapid and effective treatment of, among other things, acute allergic reactions. The product has been launched in the Nordics through Unimedic Pharma, where successively rising order values indicate a gradually increasing adoption. The next step is Europe, where the global pharmaceutical company Glenmark Pharmaceuticals is expected to submit the first marketing applications during Q4-26/Q1-27, with an initial focus on Germany. In parallel, a formal NDA application to the FDA is estimated for H2-26, where increasing partner interest is confirmed by over 50 meetings at BIO International and subsequent confidentiality agreements. The cash (10.4 MSEK) is estimated to last until Q4-26, which is why a financing need arises. The situation is, however, stronger than during the last financing, supported by the Glenmark agreement, an upcoming NDA application, and strengthened Nordic foothold. Through a DCF and rNPV valuation, a risk-adjusted net present value of 1.03 kr per share is derived in a Base scenario.
·27.8.Someone with Swedbank has bought a decent number last week. One can hope that it's the new addition accumulating.
It will be interesting if they will buy in 2029. AcuCort's warrant program fully subscribed yesterday at 13:50 ∙ News overview (AI) AcuCort has successfully completed its latest incentive program with warrants, which achieved full participation from key employees. This milestone reflects strong internal confidence in the company's strategic direction and the commercialization of its flagship product, the oral film Zeqmelit. In addition, the company highlighted its scientific progress with recent journal publications in its latest newsletter. The 2026/2029 warrant program comprises up to 1.8 million warrants, of which 1.5 million have been transferred to four key employees, and 300,000 are reserved for future hires. Each warrant entitles the holder to subscribe for one new share in AcuCort AB between September 1 and December 30, 2029, at a subscription price of 1.34 SEK. The final warrant premium was set at 0.07 SEK per warrant, calculated using the Black-Scholes model by PwC. AcuCort's August 2026 newsletter highlighted two scientific articles recently published in the Journal of Market Access & Health Policy. The company's primary product, Zeqmelit, is an approved and marketed oral film in Sweden, Denmark, Norway, and Finland.
·26.8.I bet they are down to 7 million in cash now. Earliest sale for Glenmark in 2028, so they need at least 50 million. Issue price 20 øre?- ·19.8.AcuCort Q2: Rising revenue, US push ahead today at 08:28 ∙ News overview (AI) AcuCort reported increased revenue for the second quarter of 2026, driven by commercial deliveries of the company's oral film Zeqmelit. Although net loss increased slightly, the company made significant regulatory progress towards entering the US market. Important milestones included securing an FDA agreement on the company's pediatric investigation plan and obtaining a waiver, which paves the way for a planned US marketing application. Revenue in Q2 2026 rose to SEK 1.16 million from SEK 0.16 million in Q2 2025, while net loss increased to SEK 8.20 million. AcuCort secured an FDA agreement on its pediatric investigation plan and a renewed Small Business Waiver, which are important steps towards the company's planned US drug application in 2026. The company delivered its first Nordic order for Zeqmelit, generating SEK 1.1 million, and partnered with Glenmark Pharmaceuticals for European distribution. AcuCort ended the quarter with cash holdings of SEK 10.37 million. https://www.nordnet.dk/markedet/nyheder/18f2c3e3-9158-4680-88a3-b2d3043300f2Big words as usual from the CEO. Q3 will end with zero revenue. They have 10 million in cash, and increased costs. Here comes big utvaninc
- ·7.8.AcuCort changes date for publication of interim report for the second quarter of 2026 The life science company Acucort postpones the publication of its interim report for January-June 2026 to August 19 from the previously announced August 12. The company states that the change is made to ensure that the report is completed with the necessary quality and undergoes usual review and approval before publication.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
25 päivää sitten
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8.9. · Muokattuhttps://analystgroup.se/bolag/acucort/kommentar-pa-acucorts-beviljade-varumarkesskydd-av-zeqmelit-i-ukraina Our view on AcuCort as an investment AcuCort is a pharmaceutical company that has developed the innovative oral film Zeqmelit®, based on the corticosteroid substance dexamethasone for rapid and effective treatment of, among other things, acute allergic reactions. The product has been launched in the Nordics through Unimedic Pharma, where successively rising order values indicate a gradually increasing adoption. The next step is Europe, where the global pharmaceutical company Glenmark Pharmaceuticals is expected to submit the first marketing applications during Q4-26/Q1-27, with an initial focus on Germany. In parallel, a formal NDA application to the FDA is estimated for H2-26, where increasing partner interest is confirmed by over 50 meetings at BIO International and subsequent confidentiality agreements. The cash (10.4 MSEK) is estimated to last until Q4-26, which is why a financing need arises. The situation is, however, stronger than during the last financing, supported by the Glenmark agreement, an upcoming NDA application, and strengthened Nordic foothold. Through a DCF and rNPV valuation, a risk-adjusted net present value of 1.03 kr per share is derived in a Base scenario.
- ·27.8.Someone with Swedbank has bought a decent number last week. One can hope that it's the new addition accumulating.It will be interesting if they will buy in 2029. AcuCort's warrant program fully subscribed yesterday at 13:50 ∙ News overview (AI) AcuCort has successfully completed its latest incentive program with warrants, which achieved full participation from key employees. This milestone reflects strong internal confidence in the company's strategic direction and the commercialization of its flagship product, the oral film Zeqmelit. In addition, the company highlighted its scientific progress with recent journal publications in its latest newsletter. The 2026/2029 warrant program comprises up to 1.8 million warrants, of which 1.5 million have been transferred to four key employees, and 300,000 are reserved for future hires. Each warrant entitles the holder to subscribe for one new share in AcuCort AB between September 1 and December 30, 2029, at a subscription price of 1.34 SEK. The final warrant premium was set at 0.07 SEK per warrant, calculated using the Black-Scholes model by PwC. AcuCort's August 2026 newsletter highlighted two scientific articles recently published in the Journal of Market Access & Health Policy. The company's primary product, Zeqmelit, is an approved and marketed oral film in Sweden, Denmark, Norway, and Finland.
- ·26.8.I bet they are down to 7 million in cash now. Earliest sale for Glenmark in 2028, so they need at least 50 million. Issue price 20 øre?
- ·19.8.AcuCort Q2: Rising revenue, US push ahead today at 08:28 ∙ News overview (AI) AcuCort reported increased revenue for the second quarter of 2026, driven by commercial deliveries of the company's oral film Zeqmelit. Although net loss increased slightly, the company made significant regulatory progress towards entering the US market. Important milestones included securing an FDA agreement on the company's pediatric investigation plan and obtaining a waiver, which paves the way for a planned US marketing application. Revenue in Q2 2026 rose to SEK 1.16 million from SEK 0.16 million in Q2 2025, while net loss increased to SEK 8.20 million. AcuCort secured an FDA agreement on its pediatric investigation plan and a renewed Small Business Waiver, which are important steps towards the company's planned US drug application in 2026. The company delivered its first Nordic order for Zeqmelit, generating SEK 1.1 million, and partnered with Glenmark Pharmaceuticals for European distribution. AcuCort ended the quarter with cash holdings of SEK 10.37 million. https://www.nordnet.dk/markedet/nyheder/18f2c3e3-9158-4680-88a3-b2d3043300f2Big words as usual from the CEO. Q3 will end with zero revenue. They have 10 million in cash, and increased costs. Here comes big utvaninc
- ·7.8.AcuCort changes date for publication of interim report for the second quarter of 2026 The life science company Acucort postpones the publication of its interim report for January-June 2026 to August 19 from the previously announced August 12. The company states that the change is made to ensure that the report is completed with the necessary quality and undergoes usual review and approval before publication.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | NON | NON | ||
| 9 090 | SHB | AVA | ||
| 7 000 | SHB | AVA | ||
| 23 910 | SHB | NON | ||
| 1 000 | AVA | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 19.8. | ||
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 19.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
25 päivää sitten
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 19.8. | ||
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 14.11.2025 | ||
2025 Q2 -tulosraportti 19.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8.9. · Muokattuhttps://analystgroup.se/bolag/acucort/kommentar-pa-acucorts-beviljade-varumarkesskydd-av-zeqmelit-i-ukraina Our view on AcuCort as an investment AcuCort is a pharmaceutical company that has developed the innovative oral film Zeqmelit®, based on the corticosteroid substance dexamethasone for rapid and effective treatment of, among other things, acute allergic reactions. The product has been launched in the Nordics through Unimedic Pharma, where successively rising order values indicate a gradually increasing adoption. The next step is Europe, where the global pharmaceutical company Glenmark Pharmaceuticals is expected to submit the first marketing applications during Q4-26/Q1-27, with an initial focus on Germany. In parallel, a formal NDA application to the FDA is estimated for H2-26, where increasing partner interest is confirmed by over 50 meetings at BIO International and subsequent confidentiality agreements. The cash (10.4 MSEK) is estimated to last until Q4-26, which is why a financing need arises. The situation is, however, stronger than during the last financing, supported by the Glenmark agreement, an upcoming NDA application, and strengthened Nordic foothold. Through a DCF and rNPV valuation, a risk-adjusted net present value of 1.03 kr per share is derived in a Base scenario.
- ·27.8.Someone with Swedbank has bought a decent number last week. One can hope that it's the new addition accumulating.It will be interesting if they will buy in 2029. AcuCort's warrant program fully subscribed yesterday at 13:50 ∙ News overview (AI) AcuCort has successfully completed its latest incentive program with warrants, which achieved full participation from key employees. This milestone reflects strong internal confidence in the company's strategic direction and the commercialization of its flagship product, the oral film Zeqmelit. In addition, the company highlighted its scientific progress with recent journal publications in its latest newsletter. The 2026/2029 warrant program comprises up to 1.8 million warrants, of which 1.5 million have been transferred to four key employees, and 300,000 are reserved for future hires. Each warrant entitles the holder to subscribe for one new share in AcuCort AB between September 1 and December 30, 2029, at a subscription price of 1.34 SEK. The final warrant premium was set at 0.07 SEK per warrant, calculated using the Black-Scholes model by PwC. AcuCort's August 2026 newsletter highlighted two scientific articles recently published in the Journal of Market Access & Health Policy. The company's primary product, Zeqmelit, is an approved and marketed oral film in Sweden, Denmark, Norway, and Finland.
- ·26.8.I bet they are down to 7 million in cash now. Earliest sale for Glenmark in 2028, so they need at least 50 million. Issue price 20 øre?
- ·19.8.AcuCort Q2: Rising revenue, US push ahead today at 08:28 ∙ News overview (AI) AcuCort reported increased revenue for the second quarter of 2026, driven by commercial deliveries of the company's oral film Zeqmelit. Although net loss increased slightly, the company made significant regulatory progress towards entering the US market. Important milestones included securing an FDA agreement on the company's pediatric investigation plan and obtaining a waiver, which paves the way for a planned US marketing application. Revenue in Q2 2026 rose to SEK 1.16 million from SEK 0.16 million in Q2 2025, while net loss increased to SEK 8.20 million. AcuCort secured an FDA agreement on its pediatric investigation plan and a renewed Small Business Waiver, which are important steps towards the company's planned US drug application in 2026. The company delivered its first Nordic order for Zeqmelit, generating SEK 1.1 million, and partnered with Glenmark Pharmaceuticals for European distribution. AcuCort ended the quarter with cash holdings of SEK 10.37 million. https://www.nordnet.dk/markedet/nyheder/18f2c3e3-9158-4680-88a3-b2d3043300f2Big words as usual from the CEO. Q3 will end with zero revenue. They have 10 million in cash, and increased costs. Here comes big utvaninc
- ·7.8.AcuCort changes date for publication of interim report for the second quarter of 2026 The life science company Acucort postpones the publication of its interim report for January-June 2026 to August 19 from the previously announced August 12. The company states that the change is made to ensure that the report is completed with the necessary quality and undergoes usual review and approval before publication.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | NON | NON | ||
| 9 090 | SHB | AVA | ||
| 7 000 | SHB | AVA | ||
| 23 910 | SHB | NON | ||
| 1 000 | AVA | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt